Drug manufacturer Astellas will let 340B covered entities using “a compliant 340B inventory replenishment model” count accumulations of its antifungal Cresemba under its old National Drug Code toward replenishment of equal quantities under the product’s corresponding new NDC, the company says in a public notice.
The U.S. Health Resources and Services Administration posted Astellas’ notice on the HRSA website last week. The company updated Cresemba’s NDC on Nov. 14. The medicine is used to treat rare mold infections that usually affect only people with weakened immune systems.
Drug manufacturer Astellas will let 340B covered entities using “a compliant 340B inventory replenishment model” count accumulations of its antifungal Cresemba under its old National Drug Code toward replenishment of equal quantities under the product’s corresponding new NDC, the company says in a public notice.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.